COVID-19 vaccine breakthroughs in cancer patients on the rise due to omicron

As Trump’s second term nears, Republican support for NIH is at a low point
By stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research

The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.

Argonne National Laboratory receives $22M from ARPA-H to accelerate cancer therapy, vaccine discoveries using AI

The U.S. Department of Energy’s Argonne National Laboratory will use its world-leading capabilities in artificial intelligence and high-performance computing to research novel ways to fight cancer and advance vaccine discovery.

November 22, 2024

Vol.50 No.44

In Brief

Fred Hutch, UW, and Seattle Children’s consortium researchers receive $1.7M from Breast Cancer Research Foundation

Six Fred Hutch/University of Washington/Seattle Children’s Cancer Consortium scientists received $1.7M in grants from Breast Cancer Research Foundation to launch or continue studies aimed at improving outcomes in breast cancer.

November 15, 2024

Vol.50 No.43

Clinical Roundup

Data from Gardasil 9 studies reinforce importance of gender-neutral HPV vaccination in adults

Clinical and real-world data for the 9-valent human papillomavirus vaccine, Gardasil 9, evaluating the burden and incidence of certain HPV-related cancers and diseases, were presented at the International Papillomavirus Conference 2024 in Edinburgh, UK, from Nov. 12-15.

November 15, 2024

Vol.50 No.43

In Brief

Oxford team receives $800K from CRUK to create vaccine for ovarian cancer

Scientists at the University of Oxford are designing OvarianVax, a vaccine which teaches the immune system to recognise and attack the earliest stages of ovarian cancer. The team will receive up to £600,000 (approximately US$800,000) for the study over the next three years to support lab research into the vaccine.

October 04, 2024

Vol.50 No.37

Clinical Roundup

Adjuvant treatment with cancer vaccine + Keytruda shows continued improvement in RFS and DMFS in resected high-risk advanced melanoma

Follow-up data from the phase IIb randomized KEYNOTE-942/mRNA-4157-P201 study, a clinical trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy, in combination with Keytruda in patients with resected high-risk melanoma (stage 3/4) following complete resection.

September 20, 2024

Vol.50 No.35

COVID-19 vaccine breakthroughs in cancer patients on the rise due to omicron

YOU MAY BE INTERESTED IN

As Trump’s second term nears, Republican support for NIH is at a low point
By stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research

Argonne National Laboratory receives $22M from ARPA-H to accelerate cancer therapy, vaccine discoveries using AI

Fred Hutch, UW, and Seattle Children’s consortium researchers receive $1.7M from Breast Cancer Research Foundation

Data from Gardasil 9 studies reinforce importance of gender-neutral HPV vaccination in adults

Oxford team receives $800K from CRUK to create vaccine for ovarian cancer

Adjuvant treatment with cancer vaccine + Keytruda shows continued improvement in RFS and DMFS in resected high-risk advanced melanoma

Renew today!

Subscriber content

Never miss an issue!

Login

COVID-19 vaccine breakthroughs in cancer patients on the rise due to omicron

YOU MAY BE INTERESTED IN

As Trump’s second term nears, Republican support for NIH is at a low pointBy stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research

Argonne National Laboratory receives $22M from ARPA-H to accelerate cancer therapy, vaccine discoveries using AI

Fred Hutch, UW, and Seattle Children’s consortium researchers receive $1.7M from Breast Cancer Research Foundation

Data from Gardasil 9 studies reinforce importance of gender-neutral HPV vaccination in adults

Oxford team receives $800K from CRUK to create vaccine for ovarian cancer

Adjuvant treatment with cancer vaccine + Keytruda shows continued improvement in RFS and DMFS in resected high-risk advanced melanoma

Never miss an issue!

Login

As Trump’s second term nears, Republican support for NIH is at a low point
By stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research